Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jaguar Animal Health ( (JAGX) ) has issued an update.
On April 24, 2026, Jaguar Health received a Nasdaq Hearings Panel decision allowing the company to maintain its Nasdaq Capital Market listing, provided it restores compliance with the $1.00 minimum bid price rule by May 15, 2026, by sustaining a closing bid of at least $1.00 for ten consecutive business days. The panel will retain jurisdiction until September 1, 2026, and Jaguar faces potential delisting if it fails to meet the bid price requirement or any other Nasdaq listing rules during this period.
To support regaining compliance, Jaguar’s shareholders approved a reverse stock split at a special meeting on April 20, 2026, and the board authorized a 1-for-35 split of common shares, which will take effect at 12:01 a.m. Eastern Time on April 30, 2026. The split, which does not change the total authorized share count, consolidates every 35 existing shares into one, adjusts outstanding equity awards and their exercise prices proportionately, eliminates fractional shares via cash payments, and will see JAGX continue trading on a split-adjusted basis on Nasdaq under a new CUSIP from April 30, 2026.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
The score is weighed down primarily by weak financial performance (persistent large losses and negative equity) and bearish technicals (below key moving averages with negative MACD). Corporate actions provide some support via financing flexibility, debt/royalty relief, and steps toward Nasdaq compliance, but delisting/dilution risk remains significant; valuation offers limited help due to negative earnings and no dividend.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. is a biopharmaceutical company that develops novel, plant-based prescription drugs for complex gastrointestinal diseases. Through subsidiaries Napo Pharmaceuticals and Napo Therapeutics, it focuses on crofelemer-based treatments for rare and orphan GI disorders, while joint venture Magdalena Biosciences targets plant-derived prescription medicines for mental health indications.
Average Trading Volume: 491,996
Technical Sentiment Signal: Sell
Current Market Cap: $5.05M
See more insights into JAGX stock on TipRanks’ Stock Analysis page.